News & Events about Syndax Pharmaceuticals.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX Get Rating) has received an average recommendation of Moderate Buy from the seven ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have assigned...
Syndax Announces Pricing of $150 Million Public Offering of Common Stock Syndax Announces Pricing of $150 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass., Dec. 6, 2022 WALTHAM, Mass., Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ('Syndax,' the...
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer PR Newswire WALTHAM, Mass., Dec. 2, 2022 WALTHAM, Mass., Dec. 2, 2022 /PRNewswire/ --Syndax Pharmaceuticals, Inc. (Nasdaq...
Ticker Report
3 months ago
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX Get Rating) have received a consensus rating of Moderate Buy from the six analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and ...
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX Get Rating) CEO Michael A. Metzger sold 29,606 shares of the companys stock in a transaction dated Friday, September 30th. The shares were sold at an average price of $25.02, for a total transaction of $740,742.12. Following the sale, the chief executive ...